Mobotinib (mobosetinib) medication experience and case sharing for lung cancer patients

Mobocertinib, also known as mobocertinib, is an oral targeted drug specifically used to treat patients with non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations. Although this mutation type is uncommon in lung cancer, it does not respond well to traditional EGFR-TKI treatment, so treatment options are limited. The advent of Mobotinib provides new hope for such "refractory" patients. This article will conduct a comprehensive analysis focusing on patient medication experience, therapeutic response, side effect management and sharing of real cases.

First of all, in terms of efficacy, mobotinib has shown good results in multiple international clinical trials. Data show that in patients with EGFR 20 insertion mutations whose disease still progresses after receiving at least one platinum-containing chemotherapy, the objective response rate (ORR) of this drug reaches about 28-35%, and some patients even achieve significant reduction in lesions or even complete response. Especially in patients with metastatic lesions (such as lungs, bones, and brain), it also shows a certain degree of activity. A 55 female patient from Guangdong was diagnosed with EGFR 20Insertion mutation type of advanced lung adenocarcinoma. After failure of chemotherapy combined with immunity, she started taking mobotinib. A three-month reviewCT showed that the tumor shrank by about 40% and clinical symptoms such as shortness of breath and fatigue were significantly relieved. Such cases reflect the positive effect of this drug in the real world.

However, patients also commonly face some adverse reactions during medication, among which diarrhea is the most common, followed by rash, nausea, loss of appetite, etc. Some patients may develop grade 3 or above diarrhea and need to temporarily discontinue the drug or reduce the dose. For example, a 70-year-old male patient developed diarrhea 6-7 times a day within two weeks of taking the medicine. After being guided by a doctor to use antidiarrheal drugs and adjust the dose appropriately, the condition improved significantly, and treatment continued without interruption. Experience shows that educating patients in advance and taking preventive medication can effectively control side effects and improve compliance and quality of life.

In addition, Mobotinib is a targeted drug that is taken orally once a day, and its simple medication method also provides patients with higher life convenience. Most patients say it is easier to tolerate than intravenous chemotherapy or frequent hospitalizations, especially for older or frail lung cancer patients. For example, a 65-year-old female patient takes medicine on time at home, cooperates with regular reviews, and maintains a relatively normal life rhythm and mental state. She emphasized that "although the side effects are obvious, compared with the previous chemotherapy, daily life is more comfortable and relaxed after taking Mobotinib."

In actual clinical practice, doctors usually develop individualized medication plans based on factors such as the patient's weight, liver and kidney function, and comorbidities. Some patients may start at a standard dose, while others may start at a lower dose and gradually increase the dose to assess tolerance. Generally speaking, Mobotinib is not suitable for all lung cancer patients, but targets people with specific gene mutations. Therefore, accurate genetic testing must be completed before taking the drug.

To sum up, as a specialized targeted drug targeting EGFR exon 20 insertion mutations, mobotinib brings the opportunity to extend survival and improve quality of life for many lung cancer patients in the context of limited treatment options. Although there are some side effects, with proper management and individualized treatment strategies, most patients can benefit from it. In the future, with the accumulation of more real-world data, the clinical positioning of mobotinib will be clearer and it is expected to play greater value in first-line treatment and even combination regimens. For eligible patients, it is certainly a new option worth trying.

References：https://en.wikipedia.org/wiki/Mobocertinib